Royal College of Surgeons in Ireland
Browse

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art

Download (916.43 kB)
journal contribution
posted on 2023-02-10, 13:42 authored by Habib Yaribeygi, Mina Maleki, Alexandra ButlerAlexandra Butler, Tannaz Jamialahamdi, Amirhossein Sahebkar

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a class of newly introduced antidiabetic drugs with potent hypoglycemic effects. Recent evidence suggests that these drugs have extraglycemic impacts and are therefore able to provide additional benefits beyond glucose lowering. Mitochondrial dysfunction is a central facet of many disorders that negatively impacts many tissues and organs, especially in the setting of diabetes. Therefore, it would be hugely beneficial if an antidiabetic drug could also provide mitochondrial benefits to improve cellular function and reduce the risk of diabetic complications. In this review, we have surveyed the literature for possible mitochondrial benefits of SGLT2is and we discuss the possible mechanisms involved. 

History

Comments

The original article is available at https://www.excli.de/

Published Citation

Yaribeygi H, Maleki M, Butler AE, Jamialahamdi T, Sahebkar A. Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art . EXCLI Journal. 2023;22:53–66.

Publication Date

4 January 2023

PubMed ID

36814854

Department/Unit

  • RCSI Bahrain

Publisher

University of Mainz

Version

  • Published Version (Version of Record)